Checkout
After Shingles Standout, Glaxo Hunts for the Next Vaccines
- Drugmaker is targeting respiratory virus that impacts kids
- Glaxo aims to halve the time it takes to develop vaccines
Vaccines are set to play a bigger role as Glaxo moves ahead with plans to separate its consumer health division.
Photographer: Georges Gobet/AFP via Getty ImagesThis article is for subscribers only.
GlaxoSmithKline Plc is taking aim at a virus that causes serious lung infections and kills tens of thousands of children each year, hoping to replicate the success of its last blockbuster vaccine.
Experimental shots targeting respiratory syncytial virus, or RSV, are the top pipeline priority for Glaxo’s vaccines unit, Emmanuel Hanon, its research and development head, said in an interview. Glaxo plans to move those vaccines into the final stage of testing by the end of 2020, he said.